Avicena to Present at 9th Annual Acumen BioFin Healthcare Conference

Expansion of Drug Pipeline and Advancement of Clinical Programs

Palo Alto, Calif. (October 8, 2007) — Avicena Group, Inc. (OTCBB:AVGO), a late-stage biotechnology company that develops central nervous system therapeutics for neurodegenerative disorders, announced today that it will be a presenting company at the 9th Annual Acumen BioFin Healthcare Conferenceto be held November 5-6, 2007 at the New York Palace Hotel. The company's chief executive officer, Belinda Tsao-Nivaggioli, Ph.D., will present an overview of the company and its clinical programs, including an update on activities to build its drug pipeline and investigate new delivery vehicles to enhance the bioavailability of its lead drug candidates. Dr. Tsao-Nivaggioli will be presenting on Monday, November 5 at 10:15 a.m. (EDT) in the Spellman room(5th floor). For more information on this event please visit: http://www.rodmanandrenshaw.com/conferences.

To participate in a live audio and visual webcast of Dr. Tsao-Nivaggioli's presentation please log onto Avicena's corporate website at www.avicenagroup.com at least fifteen minutes prior to the start of the presentation to download any necessary materials. An archive of this event will be available in the investor relations section of the website for 90 days.

ABOUT AVICENA

Avicena Group, Inc. (OTCBB:AVGO) is a Palo Alto, California based late stage biotechnology company that develops central nervous system therapeutics for neurodegenerative diseases. The company's core technologies, supported by a robust IP portfolio, have broad applications in both pharmaceuticals and dermaceuticals. Avicena's pharmaceutical program centers on rare neurological disorders (orphan diseases). Near term, the company plans to initiate a confirmatory Phase III trial in ALS and a Phase III trial in Huntington's disease to accompany the ongoing NIH Phase III trail in Parkinson's disease. Avicena's science is well established and its products are safe and well tolerated. Unlike traditional biotechnology companies, Avicena's clinical programs are largely funded by government and non-profit organizations. Avicena presently derives revenue from the sale of proprietary dermaceutical ingredients to skin care manufacturers.

Contact:
The Ruth Group (on behalf of Avicena Group®)
Sara Ephraim / (investors)
(646) 536-7029 / 7002
sephraim@theruthgroup.com

Janine McCargo / Jason Rando (media)
(646) 536-7033 / 7025
jmccargo@theruthgroup.com / jrando@theruthgroup.com